Leadership of Our Expert and Advisory Committees

Canada’s Drug Agency is announcing recent and upcoming changes to the leadership of our Canadian Drug Expert Committee (CDEC), pan-Canadian Oncology Drug Review Expert Review Committee (pERC), and Patient and Community Advisory Committee (PCAC).

Dr. Peter Jamieson has been appointed incoming Chair of CDEC, Dr. Catherine Moltzan has been appointed incoming Chair of pERC, and Beth Kidd was appointed for a 7-month term as the Acting Chair of the PCAC on March 1, 2024.

Dr. Jamieson has been appointed for a 3-year term that begins October 1, 2024, and he will succeed Dr. James Silvius, who has served as Chair for 11 years. Dr. Jamieson is an experienced practising family physician and hospitalist in Alberta. He is the Vice-President, Quality and Chief Medical Officer at Alberta Health Services and a clinical professor at the University of Alberta’s Cumming School of Medicine. Dr. Jamieson has served as a member of CDEC since 2011.

Dr. Catherine Moltzan has been appointed for a 3-year term that begins October 1, 2024, and she will succeed Dr. Maureen Trudeau, who has served as Chair for 11 years. Dr. Moltzan is a hematologist and serves on the medical staff of CancerCare Manitoba and the Winnipeg Regional Health Authority. She is also an associate professor in the Department of Internal Medicine at the University of Manitoba and is currently a medical advisor for Quality, Patient Safety, and Risk at CancerCare Manitoba. Dr. Moltzan has served as a member of pERC since 2015.

Beth Kidd has been a member of the PCAC since its inception and succeeds Marney Paradis, the committee’s inaugural Chair appointed in 2019, as the Acting Chair. Beth is the Executive Director of the Health Coalition of Alberta, which represents more than 120 patient groups and health charities in the province. Beth is also on the Board of Directors of the Dementia Network of Calgary and Research Canada. Beth lives with chronic migraines and is a moderator and organizer of Migraine Warriors Alberta.

About the Committees

As part of the Reimbursement Review process, CDEC and pERC make Reimbursement Recommendations for non-oncology and oncology drugs, respectively, to participating public drug plans. The PCAC provides advice on how best to ensure the voices of those with lived and living experiences accessing health care are reflected and embedded in the organization’s work.

The complete list of members of each committee is available on our website.